Logo wahanariau.com
  2. Boehringer ingelheim

Boehringer ingelheim

Index
Globenewswire

Boehringer Ingelheim and Palatin Technologies to Develop Potential First-in-class Melanocortin Receptor Targeted Treatment for Patients with Retinal Diseases

Selasa, 19 Agustus 2025 - 20:07:57 Wib
Globenewswire

Boehringer and Click Therapeutics’ Investigational Prescription Digital Therapeutic CT-155 Meets Primary Endpoint in CONVOKE Study for Negative Symptoms in Schizophrenia

Jumat, 08 Agustus 2025 - 01:13:46 Wib
Globenewswire

Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies

Selasa, 29 Juli 2025 - 03:31:09 Wib
Globenewswire

First Half of 2025: Solid Growth, Investments and Pipeline Progress Pave the Way for Two Key Launches in H2

Kamis, 24 Juli 2025 - 21:27:34 Wib
Globenewswire

Boehringer Ingelheim Initiates Phase II Study of BI 1815368, a Potential First-in-class Oral Treatment for Diabetic Macular Edema

Senin, 07 Juli 2025 - 21:29:54 Wib
Globenewswire

Boehringer Ingelheim and Eko Health Inc. Enter Digital Health Collaboration to Improve Heart Murmur Detection in Dogs

Selasa, 10 Juni 2025 - 17:30:00 Wib
Globenewswire

Boehringer Ingelheim to Present Early Clinical Evidence of Innate Immune Modulation and Anti-tumor Activity Via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

Jumat, 23 Mei 2025 - 21:38:35 Wib
Globenewswire

Global Phase III Trials Demonstrate That Nerandomilast Slowed Lung Function Decline in IPF and PPF, with Similar Discontinuation Rates to Placebo

Rabu, 21 Mei 2025 - 02:57:23 Wib
Globenewswire

Boehringer Ingelheim Starts Phase II Study of its Potential First-in-class Oral Compound as a Treatment for Geographic Atropy

Selasa, 06 Mei 2025 - 21:58:37 Wib
Globenewswire

Breaking New Ground in Mental Health Research: Oxford University, Boehringer Ingelheim, and Cumulus Neuroscience Launch First of its Kind Study Investigating the Day-to-day Experience of Patients with Psychiatric Disorders

Rabu, 30 April 2025 - 03:29:13 Wib
Globenewswire

Boehringer’s New Zongertinib Data Demonstrate Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-mutant Advanced NSCLC

Selasa, 29 April 2025 - 03:09:24 Wib
Globenewswire

New Survey Shows that Over 90% of Animal Owners Trust and Appreciate Veterinary Teams but Underestimate the Demands of the Profession

Kamis, 24 April 2025 - 21:33:32 Wib
Globenewswire

Boehringer Ingelheim and Tessellate Bio Partner to Develop First-in-class Precision Treatments for People with Hard-to-treat Cancers

Rabu, 23 April 2025 - 21:18:32 Wib
Globenewswire

Boehringer Ingelheim Announces Succession Chairmen Shareholders’ Committee and Board of Managing Directors

Kamis, 17 April 2025 - 23:31:28 Wib
Globenewswire

Boehringer Ingelheim Strengthens Antibody-drug Conjugate Portfolio with New NBE Therapeutics R&D Center in Basel

Kamis, 03 April 2025 - 14:30:00 Wib
Globenewswire

Boehringer Ingelheim Reaches More Patients in 2024 and Prepares New Medicine Launches

Rabu, 02 April 2025 - 23:54:20 Wib
Globenewswire

Boehringer Ingelheim Launches New Trivalent Poultry Vaccine, Includes Protection Against H5 Avian Influenza

Senin, 24 Februari 2025 - 17:00:00 Wib
Globenewswire

Boehringer Ingelheim and Partners Start Clinical Development of a First-in-class, Inhaled Gene Therapy for People with Cystic Fibrosis

Kamis, 20 Februari 2025 - 23:26:39 Wib
Globenewswire

Boehringer’s Zongertinib Receives Priority Review from U.S. FDA for the Treatment of HER2 (ERBB2)-mutant Advanced Non-small Cell Lung Cancer

Rabu, 19 Februari 2025 - 23:10:27 Wib
Globenewswire

Boehringer’s Nerandomilast Meets Primary Endpoint in Phase III Study FIBRONEER™-ILD, in Progressive Pulmonary Fibrosis

Senin, 10 Februari 2025 - 20:30:00 Wib
Globenewswire

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Kamis, 16 Januari 2025 - 22:30:00 Wib
Globenewswire

Boehringer’s Focus on Health Equity Drives Significant Upgrade in Access to Medicine Index Ranking

Selasa, 19 November 2024 - 20:30:00 Wib
Globenewswire

Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative Join Forces to Combat Vision Loss from Diabetes

Selasa, 12 November 2024 - 17:30:00 Wib
Globenewswire

Boehringer Ingelheim and WHO Foundation Join Forces to Promote Equitable Access to Healthcare and Increase Efforts for Suicide Prevention

Selasa, 15 Oktober 2024 - 17:00:00 Wib
Globenewswire

Boehringer Receives U.S. FDA Breakthrough Therapy Designation and Initiates Two Phase III Trials in MASH for Survodutide

Selasa, 08 Oktober 2024 - 14:00:00 Wib